PYXS
Pyxis Oncology, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.72
P/S
6.71
EV/EBITDA
-1.23
DCF Value
$1.84
FCF Yield
-68.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
103.1%
Operating Margin
-609.2%
Net Margin
-574.5%
ROE
-101.8%
ROA
-87.0%
ROIC
-117.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.0M | $-18.1M | $-0.29 |
| FY 2025 | $13.9M | $-79.6M | $-1.28 |
| Q3 2025 | $0.00 | $-22.0M | $-0.35 |
| Q2 2025 | $2.8M | $-18.4M | $-0.30 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.42
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.